TLR7 Agonist and HBV Capsid Inhibitor Combination Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for chronic hepatitis B virus (HBV) infection, such as nucleos(t)ide analogues and pegylated interferon-alpha, have limited efficacy in achieving HBsAg loss and seroconversion, and are often poorly tolerated, necessitating the development of more effective and tolerable treatment options.
Innovation Solution
A combination therapy comprising a TLR7 agonist and an HBV capsid assembly inhibitor, administered together, to enhance immune response and disrupt HBV capsid formation, thereby reducing viral replication and promoting HBsAg clearance.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapies (nucleos(t)ide analogues and pegylated interferon-alpha) are used to treat chronic HBV infection, then viral replication is suppressed, but HBsAg loss and seroconversion are rarely achieved and treatment tolerance is poor
Solution Approach 1:
The patent combines two distinct therapeutic mechanisms: TLR7 agonists that stimulate innate immune response and HBV capsid assembly inhibitors that disrupt viral replication. This combination therapy merges immunomodulation with direct antiviral activity, aiming to achieve both HBsAg clearance and viral suppression while improving tolerability compared to interferon-based monotherapies.
Solution Approach 2:
The invention changes the therapeutic parameters by introducing oral TLR7 agonists with specific chemical structures (compounds of formula I and II) that activate immune receptors, combined with capsid inhibitors (compounds of formula III). This parameter change from parenteral interferon to oral small molecules improves tolerability while maintaining or enhancing efficacy.
2Reliability
If nucleos(t)ide analogues are administered to inhibit HBV DNA synthesis, then viral replication is reduced, but HBsAg levels are not directly affected and seroconversion rates remain very low
Solution Approach 1:
The patent segments the therapeutic approach into two distinct components: nucleos(t)ide analogues for viral replication suppression and TLR7 agonists plus capsid inhibitors for HBsAg clearance. This segmentation allows each component to target specific aspects of the disease, with the combination addressing both viral load reduction and functional cure.
Solution Approach 2:
The TLR7 agonist acts as an intermediary that bridges viral detection and immune activation. By stimulating TLR7 receptors, it triggers innate immune responses that produce interferons and other antiviral cytokines, creating a bridge between viral presence and host defense mechanisms to achieve HBsAg clearance.
3Productivity
If pegylated interferon-alpha is used to treat chronic HBV, then some patients achieve HBsAg loss and seroconversion, but the majority experience poor tolerability and treatment discontinuation
Solution Approach 1:
The patent substitutes the mechanical/administrative burden of weekly injectable interferon with oral small molecule administration. The TLR7 agonists and capsid inhibitors are administered orally, eliminating the need for injections and improving patient convenience and tolerability while maintaining therapeutic efficacy.
Data Source
AI summary
The present invention is directed to compositions and methods for treating hepatitis B virus infection. In particular, the present invention is directed to a combination therapy comprising administration of a TLR7 agonist and an HBV capsid assembly inhibitor for use in the treatment of chronic hepatitis B patient.